reterm birth is one of the major global public health problems and it is the single largest cause of neonatal
deaths. India contributes the highest number of preterm birth and deaths worldwide (~25%). From a clinical
perspective, it is of paramount importance to understand the molecular processes involved in preterm birth for
early prediction, or prevention of preterm birth.
RCB will lead the proteomics component of preterm birth project. We will be investigating the proteomics
alterations that occur at different stages of pregnancy, identify the proteins that are associated with preterm birth
and an integrative analysis of genomic and proteomic alterations in order to identify physiological molecular
pathway mechanisms that are altered in relation to preterm birth. The long-term goal for this project is to identify
the biomarkers relevant for early prediction of preterm birth or future target molecular for drug discovery.
RCB has integrated proteomics platform comprising of Triple-TOF 5600 Mass Spectrometry system (ABSciex)
and MALDI-TOF/TOF 5800 System (ABSciex), with high-end computing facility.
Applicants may apply along with the requisite documents (attested copies) pertaining to proof of date of birth,
academic/professional qualifications, experience (if any), in the prescribed format available on our websites:
www.rcb.res.in and www.rcb.ac.in. Applications should be sent to The Registrar, Regional Centre for
Biotechnology, 180 Udyog Vihar Phase 1, Gurgaon 122 016, Haryana, India, through Registered Post on or
before 31 July 2014. A soft copy of the application should be sent by e-mal to: registrar@rcb.res.in. Incomplete
applications or applications received after 31 July 2014 will not be entertained.
No comments:
Post a Comment